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ABSTRACT
Objectives: The objective of this study was to investigate the acute toxicity of standardized protodioscin rich extract (PRE) of Trigonella foenum-
graecum L (26.63% w/w; PRE).
Methods: To evaluate the toxicity of PRE, the acute toxicity of the extract on adult rats were investigated. A fixed large dose of 2 g/kg body weight of 
PRE was administrated by a single oral gavage, and 1 g/kg body weight of PRE was administered by intravenous according to the Organisation for 
Economic Co-operation and Development guidelines.
Results: In 2 weeks, PRE showed no obvious acute toxicity. There were no deaths in either group and no change in the clinical signs. The hematological 
and biochemical analyses showed some changes that returned to reference levels without impairment of homeostasis. The treatment did not induce 
untoward changes in organs as shown by histological studies. The in vivo results showed that has low toxicity.
Conclusion: PRE is safe and can be potentially used as an aphrodisiac in future studies.
Keywords: Protodioscin, Aphrodisiac, Trigonella foenum-graecum, Organisation for Economic Co-operation and Development, Toxicity, 
Histopathological studies.
INTRODUCTION
Traditional medicine is one of the most accessible tools to satisfy 
people’s healthcare need. However, limited studies on traditional 
medicinal plants hinder utilization of plant-based medicine. Therefore, 
to develop safe natural plant products, preliminary studies are 
necessary to evaluate possible risks such as undesirable side effects 
and to determine appropriate dosage levels and regimens to avoid 
overdosing or poisoning of patients [1].
Trigonella foenum-graecum L. (Fabaceae), popularly known as fenugreek, 
is an aromatic 30-60 cm tall annual herb, originating in India and Northern 
Africa and cultivated throughout China and India [2]. In traditional 
Chinese medicine, seeds are used as a tonic and to relieve edema of 
the legs. In India, it is commonly consumed as a condiment. It is used 
in indigestion, arthritis, spondylosis, baldness, diabetes mellitus, and 
hyperlipidemia [3-6]. It is also used as appetizer and galactogogues [2,7]. 
The seeds of T. foenum-graecum are used in the ayurvedic formulations 
Mustakarista and Mrtasanjivni Sura [8]. T. foenum-graecum seeds contain 
several bioactive constituents, viz., amino acid 4-hydroxy isoleucine, 
steroidal saponin - trigoneoside, trigofoenosides, protodioscin, 
protogracillin, diosgenin, alkaloid trigonelline, flavonoids, and 
mucilage [9]. Protodioscin, 26-O-β-d-glycopyranosyl-22-hydroxyfurost-5 
ene-3β, 26-diol-3-O-β-diglucorhamnoside, belongs to the furostanol class 
of saponin, having a molecular weight 1049.2 g mole−1. It is freely soluble 
in water, sparingly soluble in methanol, and insoluble in chloroform 
and ethyl acetate. Protodioscin is claimed to have aphrodisiac activity 
[10-18] due to its ability to enhance testosterone levels in the body [19]. 
Protodioscin is also reported to have anticancer activity [20].
However, there is no reported acute toxicity for protodioscin rich 
extract (PRE). Thus, it is necessary to evaluate the safety and toxicity 
of PRE to establish clinical safety and a premise for pharmacodynamic 
studies. The present study provides data on the safety of PRE by 
examining the acute toxicity of orally administered PRE to Sprague-
Dawley rats.
METHODS
Preparation of standardized PRE of T. foenum-graecum
T. foenum-graecum powder (200 g) was defatted by hot reflux on 
water bath using hexane (3×500 ml)  for 4 hrs. The defatted material 
was subjected to hot reflux extraction on water bath using 20% 
methanol (3×700 ml) for 3 hrs. Methanol was used for denaturation 
of glycosidase enzymes which are responsible for the breakdown of 
the glycosides. The pooled extract was filtered, concentrated under 
reduced pressure,  and  then partitioned with  chloroform  (4×500 ml). 
Chloroform layer was discarded, and aqueous part was partitioned with 
ethyl acetate (3×500 ml). Ethyl acetate layer discarded and the aqueous 
layer was partitioned with n-butanol (3×400 ml). N-butanol fraction 
was evaporated in rotary flask evaporator to get the solid residue 
(Yield-8% w/w). Thus, prepared butanolic fraction was analyzed for 
the protodioscin content using developed HPTLC method [21]. The 
protodioscin content was found to be 26.63% w/w.
Animals
Wistar albino rats of either sex of 6-12 months age, 
weighting  250-300  g,  were  procured  from  the  Animal  Vaccines 
Institute, Gandhinagar. The animals were housed in polypropylene 
cages with stainless steel grill tops and provided with bedding of clean 
paddy husk. The animals were acclimatized to laboratory conditions for 
1-week before treatment. All animals were maintained at a controlled 
temperature [22±2°C] under 12-hrs light/dark cycles and were allowed 
free access to food and water. The protocol of the study was approved 
by the Institutional Ethics Committee of the Ramanbhai Patel College of 
Pharmacy (RPCP/IAEC/2013-2014/R-31r).
Acute toxicity
All rats of either sex were fasted overnight before treatment and 
were given food 1 hr after treatment. The hypothesis was made that 
PRE would be relatively safe because traditional healers use it for the 
treatment of various ailments. Thus, a single high dose, as recommended 
by the Organisation for Economic Co-operation and Development 
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guidelines [22] of 2.000 mg/kg and 1000 mg/kg of PRE dissolved in 
water for injection was injected via tail vein to 3 rats and administered 
per oral to 3 rats, respectively.
The animals were observed, and data were recorded at before treatment 
and 14 days after treatment. The visual observations evaluated changes 
in the skin, fur, eyes, and respiration, in addition to behavior. Blood 
(About 1 ml) was collected (on Day-0 and Day-14) from Retro-orbital 
plexus of the rat in a micro-centrifuge tube containing disodium 
EDTA as an anticoagulant. It was assessed for various hematological 
parameters such as total red blood cells; white blood cells count using 
Neubauer chamber. Blood (About 2 ml) was collected (on Day-0 and 
Day-14) and allowed to coagulate to get serum. The serum levels of 
various biochemical parameters were assessed using span diagnostic 
kits at the institute. The animals then sacrificed, and the organs (liver, 
heart, kidney, Lung, spleen, and brain) were dissected, and the gross 
histology of the organs was performed.
Statistical analysis
The data were analyzed using one-way analysis of variance with 
Bonferroni post-hoc tests for multiple comparisons using GraphPad 
Prism  (Version  19.0,  IBM  Corporation,  New  York,  NY,  USA).  p<0.05 
was considered statistically significant. Results are expressed as 
mean ± standard error mean.
RESULTS AND DISCUSSION
In general, the knowledge of adverse reactions and side effects of 
traditional medicines is gained from the experience of administering 
these medicines. Owing to the limitations of current assessment 
methods and techniques, little is known about the toxicity of traditional 
medicines. To ensure their safe use, it is crucial to assess the safety of 
traditional medicines. In this study, the fixed-dose procedure was used 
to examine the toxicity of PRE of T. foenum-graecum. After the oral and 
intravenous administration of PRE, the behavioral responses, mortality, 
hematological, biochemical, and histopathological examinations were 
carried out.
No significant toxic signs or death was observed during the 14-day 
observation period. None of the rats showed clinical toxic signs such 
as anorexia, depression, lethargy, jaundice, and dermatitis and also 
no mortality happened throughout the examination. Table 1 shows 
the changes of biochemical parameters in the sera of rats induced by 
T. foenum-graecum L. PRE after oral and intravenous administration. 
No significant (p>0.05) variations in parameters were noted between 
groups, and the levels for all blood chemistry parameters were within 
the normal range [23,24]. The hematological status for rats 14 days after 
an acute oral administration of the PRE is shown in Table 2. The change 
was insignificant and, importantly, remained within the normal range. 
Fig. 1: Histopathological examination of liver (a), kidney (b), lung (c), heart (d), spleen (e), and brain (f) after administration of 
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Table 1: Clinical biochemistry values for rats after oral and parenteral administration of protodioscin rich extract of Trigonella 
foenum-graecum L (Data are expressed as Mean±SEM)
Parameters Normal range Oral administration (n=3) Parenteral administration (n=3)
Day 0 Day 14 Day 0 Day 14
Glucose (mg/dL) 63‑165 73.79±1.55 76.83±3.88 72.45±1.277 78.04±1.174
ALP (IU/L) 26-147 78.949±18.80 48.816±5.219 79.013±18.228 132.587±3.666
AST (IU/L) 65-203 102.544±8.9 76.005±6.47 102.879±9.59 89.579±3.12
ALT (mg/dL) 16-48 41.659±2.18 30.645±3.12 45.387±3.473 36.741±4.4
Total protein (g/dL) 5.5-7.7 6.563±0.076 8.017±0.882 6.378±0.127 5.762±0.557
Albumin (g/dL) 3.6-5.5 5.328±0.173 4.948±0.128 5.254±0.168 4.772±0.123
Bilirubin (mg/dL) 0.03-0.06 0.053±0.00 0.051±0.001 0.052±0 0.060±0.09
Urea (mg/dL) 12.3-24.6 17.91±2.33 20.37±1.86 16.90±3.26 19.63±3.246
Uric acid (mg/dL) 4.7-6.7 5.4±0.77 4.5±0.235 4.7±0.819 5.2±0.480
Creatinine (mg/dL) 0.2-0.6 0.63±0.088 0.63±0.033 0.35±0.035 0.46±0.103
Blood urea nitrogen (mg/dL) 15-21 22.07±1.507 17.77±0.38 19.03±2.484 15.68±0.447
Cholesterol (mg/dL) 23-97 71.91±2.902 36.71±3.08 70.92±3.443 64.79±5.03
SEM: Standard error mean, T. foenum-graecum: Trigonella foenum-graecum
Moreover, gross and pathological examinations of the internal organs 
after hematoxylin-eosin staining reveal no pathological abnormalities 
for rats in any group (Figs. 1 and 2). Based on biochemical and 
hematological findings as well as findings of the pathological analysis of 
the major organs, it was concluded that the PRE did not show significant 
toxicity in this experiment.
Fixed-dose procedure reveals the effect of PRE on animals, thus providing 
basic information for its toxicity studies. These results suggest that the 
PRE is not toxic with an acute exposure of 2000 mg/kg BW. However, 
the fixed-dose procedure has some limitations as the applicability of 
this dose to toxicity studies for other natural medicinal extracts still 
needs to be further investigated.
Fig. 2: Histopathological examination of liver (a), kidney (b), lung (c), heart (d), spleen (e), and brain (f) after I.V. administration of 
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CONCLUSION
Results demonstrate the safety of an acute oral and intravenous 
administration of PRE in rats. The LD50 could not be evaluated at the 
given dose. However, we conducted an acute toxicity test over a relatively 
short period (2 weeks) and not a complete chronic toxicity study with 
many doses that may demonstrate cumulative toxic effects. The sub-
acute and long-term toxicity should be fully evaluated to determine the 
safety profile of PRE. Our results indicate that such additional toxicity 
testing is warranted.
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